印度在3.5年内超过了6年的API生产目标,提高了基本药品的自力更生能力。 India surpassed its six-year API production target in 3.5 years, boosting self-reliance in essential medicines.

印度通过政府奖励计划加速了国内活性药物成分的生产,在短短三年半的时间里投资40 890卢比,超过其六年目标。 India has accelerated domestic production of active pharmaceutical ingredients through government incentive schemes, with Rs 40,890 crore in investments—surpassing its six-year target—in just three and a half years. 散装药物和药品的PLI计划使当地制造了26种以前进口的主要API,避免了价值1,807.32卢比的进口,并在国内销售中产生了26,123卢比的收益。 The PLI schemes for bulk drugs and pharmaceuticals have enabled local manufacturing of 26 key APIs previously imported, avoided imports worth Rs 1,807.32 crore, and generated Rs 26,123 crore in domestic sales. 这些方案支持726个API,包括191个首次国内生产,旨在增强供应链的复原力和高价值毒品制造。 The programs support 726 APIs, including 191 first-time domestic productions, and aim to boost supply chain resilience and high-value drug manufacturing. 这两项计划持续到2028-29年,都在扩大印度在基本药品方面的自力更生能力。 Both schemes, running until 2028–29, are expanding India’s self-reliance in essential medicines.